Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by G & W Laboratories Inc..
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Alquest
SMART Biotech Ltd
Information provided by (Responsible Party):
G & W Laboratories Inc.
ClinicalTrials.gov Identifier:
NCT01447680
First received: September 22, 2011
Last updated: October 9, 2011
Last verified: October 2011

September 22, 2011
October 9, 2011
August 2011
December 2011   (final data collection date for primary outcome measure)
Concordance of positive and negative results between normal and treated plasma samples when both are tested with the same HIV and/or HCV Enzyme Linked Immunosorbant Assay (ELISA) [ Time Frame: Blood samples for HIV and HCV testing will be collected at time of consent (day 1). ] [ Designated as safety issue: No ]
There is one timepoint (day 1)for which the primary outcome measure will be assessed and data will be presented. Samples will be collected, delinked and shipped to core lab within 1 day of collection where samples will be processed and subsequently analyzed for HIV and HCV antibodies. Samples will be frozen and retained for future testing. Results of all testing of correlating SMARTplasma and normal plasma samples will be reported as either positive or negative and these results will be compared for concordance.
Same as current
Complete list of historical versions of study NCT01447680 on ClinicalTrials.gov Archive Site
  • Sensitivity and specificity of HIV and HCV antibody assays when used with SMARTplasma [ Time Frame: Blood samples for HIV and HCV testing will be collected at time of consent (day 1). ] [ Designated as safety issue: No ]
    Testing to demonstrate that SMARTplasma does not adversely affect diagnostic specificity & sensitivity of the HIV or HCV antibody assay used (no increase in rate of false positives or false negatives); however,samples from persons with early or acute infection may show a positive result when tested with SMARTplasma while those from normal plasma will test negative. Results of all testing of correlating SMARTplasma and plasma samples will be reported as either positive or negative and these results will be compared for concordance.
  • Correlation of results from two different sample types (heparin vs EDTA) [ Time Frame: Blood samples for HIV and HCV testing will be collected at time of consent (day 1). ] [ Designated as safety issue: No ]
    Testing will determine if SMARTplasma samples from collections in heparin or ethylenediaminetetraacetic acid (EDTA) tubes and the correlating SMARTstim sample results are comparable. Results of all testing of correlating heparin and EDTA samples will be reported as either positive or negative and these results will be compared for concordance.
  • Correlation of results from refrigerated versus frozen then thawed samples [ Time Frame: Blood samples for HIV and HCV testing will be collected at time of consent (day 1). ] [ Designated as safety issue: No ]
    Following testing for HIV and HCV antibodies (primary outcome measure), an aliquot of each SMARTplasma test samples will be frozen, thawed and retested for HIV and HCV antibodies side-by-side with a corresponding fresh/refrigerated (non-frozen and thawed) sample. Testing will determine if SMARTplasma samples that have been frozen and thawed prior to testing show comparable results to correlating SMARTplasma samples that have been refrigerated. Results will be reported as either positive or negative and these results will be compared for concordance.
Same as current
Not Provided
Not Provided
 
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Clinical Trial Comparing Two Types of Blood Samples (Plasma and SMARTplasma) for HIV and HCV Antibody Testing

The purpose of this study is to compare the results for HIV and/or Hepatitis C Virus antibody testing when using routine plasma versus SMARTplasma from the same blood sample. SMARTplasma is enriched for antibodies via a stimulation step of whole blood in a SMARTube™ (SMARTstim™ in the USA).

Following exposure to HIV and HCV, there is a "window period" where a person is infected with the virus but does not produce antibodies at a high enough level so they can be detected by antibody detection test methods. During this time, the person is capable of unknowingly transmitting the virus to others. SMARTstim (SMARTube)is a blood sample additive which pre-treats blood, stimulating antibody production in vitro so as to bring it to detectable levels using ELISA (or any other antibody test method). Accelerated antibody production allows antibody detection in specimens that would otherwise be below the detectable limit of antibody test kits. Plasma samples from blood pretreated with SMARTstim are referred to as "SMARTplasma".

A total of 1,600 blood samples will be collected and tested using an ELISA for HIV and HCV using FDA-approved test kits. The populations include:

  • 1000 samples from low risk individuals (blood donors) from 3 geographical locations
  • 500 samples from high risk individuals at risk for HIV from 2 geographical locations
  • 100 known HIV seropositives

This is a non-linked study; that is, no subject identifiers will be associated with the collected blood. Subjects will not receive any correspondences and will not receive any test results.

If discordant results occur between the plasma and SMARTplasma samples, those samples will be retested. A Western Blot will be performed on ELISA repeat reactive discordant samples. HCV testing using an FDA-approved assay may also be performed using retained samples.

Simple statistical methods will be performed as necessary to analyze concordance of results between the sample types in the same ELISA assay.

Secondarily, it is expected that within the scope of this study, it will be shown that:

  • Using SMARTplasma does not adversely affect diagnostic specificity of the HIV and/or HCV antibody assay used; i.e., no increase in the rate of HIV or HCV false positive results.
  • Using SMARTplasma does not adversely affect diagnostic sensitivity of the HIV and/or HCV antibody assay used; i.e., no decrease in the number of true positive samples.
  • Samples from persons with early or acute infection may show a positive result when using SMARTplasma, while those from plasma will test negative.
  • SMARTplasma samples using heparin or EDTA collection tubes and the correlating SMARTstim are comparable.
  • SMARTplasma samples that have been frozen show comparable results to correlating SMARTplasma samples that have been refrigerated.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Plasma and SMARTplasma (SMARTplasma is plasma sample from whole blood treated with SMARTstim)

Probability Sample

Laboratory Sample from low risk population (i.e., blood donors), high risk population and known positive patients.

  • Human Immunodeficiency Virus Infection
  • Hepatitis C
Not Provided
  • Blood samples, low risk population
  • Blood samples, high risk population
  • Blood samples, known HIV positive

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1600
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults ages 18-64,
  • Are not pregnant
  • Not have a life-threatening disease
  • Not immunosuppressed (HIV therapy allowed)
  • Are able to give consent, and (6) who appear healthy.

Exclusion Criteria:

  • Do not meet the inclusion criteria
  • Are enrolled in an HIV vaccine study,
  • Who have previously been enrolled in this study
Both
18 Years to 64 Years
Yes
Contact: Aaron Greenblatt, Pharm.D. (908)-753-2000 ext 3803 agreenblatt@gwlabs.com
United States
 
NCT01447680
ST-2011-HIV, Version 4
No
G & W Laboratories Inc.
G & W Laboratories Inc.
  • Alquest
  • SMART Biotech Ltd
Principal Investigator: Niel Constantine, Ph.D. University of Maryland, Baltimore County
G & W Laboratories Inc.
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP